cvs yeztugo - Search News

News

CVS, HIV and Yeztugo

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the former’s new HIV prevention drug, Yeztugo (lenacapavir), to its commercial plans for now.

· 14h

CVS Health denies coverage for breakthrough HIV drug, committing 'clear violation' of ACA

Fierce Healthcare · 1d

For now, CVS declines to cover Gilead's long-acting HIV PrEP treatment Yeztugo

1don MSN

Exclusive: CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

StockStory.org on MSN1d

Why Gilead Sciences (GILD) Shares Are Sliding Today

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS Health will not be adding the company's new HIV prevention drug, Yeztugo, to ...

STAT1d

Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Josh Nathan-Kazis

Josh Nathan-Kazis is a senior writer at Barron's, covering the healthcare industry. He is a former staff writer at the Forward, where he investigated nonprofits, covered local and national politics, ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results